Sector Expert: Jason Kolbert

Maxim Group

Image: Jason Kolbert

Jason Kolbert is a senior managing director with the Maxim Group, and the head of healthcare research as well as a covering analyst. Kolbert's career began as a chemist in the pharmaceutical industry, and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan, he joined Salomon Smith Barney as a research associate, which evolved into an 18-year career on Wall Street as a ranked biotechnology analyst. As the head of healthcare at Maxim, Kolbert manages the healthcare effort to maintain a balance of large, capitalized, relevant institutional coverage combined with the next generation of small, capitalized, emerging companies that will influence the sector. His focus is across several therapeutic areas, with an emphasis in antiviral medicine, regenerative medicine, oncology and immunology (cell therapy). Kolbert is noted for being among the first analysts to focus on the changing landscape for Hepatitis C therapy. Today Kolbert is making the same call for stem cell therapy, identifying the sector as having the potential to alter current treatment paradigms. Kolbert spent seven years at Citi Group as a traditional sellside analyst, followed by seven years on the buy side as a portfolio manager with the Susquehanna International Group. Kolbert recently returned to his analyst role after spending a year as the head of business development for a public cell therapy company. At Maxim, Kolbert and his colleagues oversee a team responsible for covering 70 companies.

Subscribe to
Streetwise Reports

Companies Commented On

  • Soligenix Inc.


Recent Interviews

2017 Small-Cap Biotech Watchlist: Takeaways for Investors (1/18/17)
2017_watchlist

Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.

Regenerative Medicine Follows the CAR T-Cell Gravy Train: Maxim Group's Jason Kolbert and Jason McCarthy (12/2/15)
sideways-blue-stemcell580

Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird") in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert (4/8/15)
brainscan580

It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised patience. Jason Kolbert of New York City-based Maxim Group relishes finding early-stage, cutting-edge, small-cap names that he believes will change the paradigm of medical practice. In this interview with The Life Sciences Report, Kolbert shares a list of favorite biotechs developing products that will command premium pricing and sustained performance in the marketplace.

Recent Quotes

"SNGX announced today that the company has received an additional $2M in funding."

— Jason Kolbert, Maxim Group (6/21/17)
more >

"INO continues to demonstrate that the company's DNA-based vaccine approach is safe and can rapidly transition to human studies."

— Jason Kolbert, Maxim Group (8/29/16)
more >

"INO announced that the phase I study of INO-4212 in healthy subjects will expand to include 125 more subjects to determine the best immunization strategy using intradermal vaccination."

— Jason Kolbert, Maxim Group (8/11/16)
more >

"SNGX's vaccine proteins are stable when heated to 104 degrees Fahrenheit over 12 weeks."

— Jason Kolbert, Maxim Group (7/18/16)
more >

"IPCI's NDA filing is coming next, followed by the PDUFA date, which sets the stage for a partnership deal."

— Jason Kolbert, Maxim Group (7/13/16)
more >

"We look forward to IPCI's NDA filing and a PDUFA date, which should pave the way for a partnership deal."

— Jason Kolbert, Maxim Group (7/5/16)
more >

"INO's ability to respond quickly to a rapidly emerging public health threat like Zika virus could be an ideal approach for controlling disease spread."

— Jason Kolbert, Maxim Group (6/20/16)
more >

"Preliminary results from SNGX's Phase 2 study in oral mucositis will be presented in Australia; positive preliminary results set the stage for a Phase 2b/3 study."

— Jason Kolbert, Maxim Group (6/7/16)
more >

more comments

"The positive preliminary results of the SGX942 Phase 2 study sets the stage for SNGX to pursue partnerships for the Phase 2/3 study."

— Jason Kolbert, Maxim Group (5/12/16)
more >

"MESO's heart failure trial is recruiting well in North America and is expected to expand more aggressively in the EU."

— Jason Kolbert, Maxim Group (5/10/16)
more >

"There is unusually strong alignment and interest by both ATHX and Healios to expand MultiStem to other indications for Japan."

— Jason Kolbert, Maxim Group (5/6/16)
more >

"The continued nondilutive government funding for SNGX's biodefense research is positive."

— Jason Kolbert, Maxim Group (5/5/16)
more >

"We expect to see IPCI's Rexista lead to a partnership opportunity."

— Jason Kolbert, Maxim Group (4/15/16)
more >

"Immunogenicity data from INO's Ebola vaccine study were positive."

— Jason Kolbert, Maxim Group (3/30/16)
more >

"SNGX's dusquetide shows preclinical efficacy against a broad spectrum of infectious bacteria."

— Jason Kolbert, Maxim Group (3/29/16)
more >

"INO continues to drive multiple oncology programs forward."

— Jason Kolbert, Maxim Group (3/29/16)
more >

"INO announced preclinical data showing that a DNA-based monoclonal antibody targeting the Chikungunya virus induced 100% protection."

— Jason Kolbert, Maxim Group (3/23/16)
more >

"SNGX does a masterful job at biodefense research with government dollars."

— Jason Kolbert, Maxim Group (3/17/16)
more >

"The rebound in MESO's valuation is justified."

— Jason Kolbert, Maxim Group (3/17/16)
more >

"INO acquired Bioject Medical's injection technology for $5.5M."

— Jason Kolbert, Maxim Group (3/14/16)
more >

"A positive outcome for ATHX's MultiStem in stroke is probable."

— Jason Kolbert, Maxim Group (3/11/16)
more >

"IPCI's overdose-resistant technology could change the dynamics of the entire drug landscape."

— Jason Kolbert, Maxim Group (2/29/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.